飛達控股(01100.HK)中期純利上升27.8%至8448.6萬港元 中期息3港仙
格隆匯8月30日丨飛達控股(01100.HK)發佈公吿,截至2022年6月30日止六個月,公司收益再創新高,同比上升27.0%至9.42億港元,有賴孟加拉工廠優異的生產效率,能迅速回應及滿足客户的需求,進一步從快速訂單需求增長中受惠。
毛利大幅上升25.1%至3.04億港元,但期內成本上漲,毛利率稍微下調0.5個百分點至32.2%(2021年中期:32.7%)。為滿足生產週期短促的快速訂單需求,集團透過提高自動化水平及優化管理,積極提升孟加拉工廠的效率。股東應占溢利上升27.8%至8448.6萬港元。董事會決議宣派中期股息每股3港仙(2021年中期:3港仙)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.